Trevena Announces Receipt of Nasdaq Delisting Notification
04 Octubre 2024 - 3:05PM
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical
company focused on the development and commercialization of novel
medicines for patients with central nervous system (CNS) disorders,
today announced that on October 4, 2024 the Company received notice
that the Nasdaq Hearings Panel (the “Panel”) had determined to
delist the Company’s common stock from The Nasdaq Stock Market LLC
(“Nasdaq”) due to the Company’s failure to comply with the minimum
stockholder’s equity requirement under Nasdaq Listing
Rule 5550(b)(1) (the “Equity Standard Rule”). As previously
disclosed, the Panel had provided the Company until October 2,
2024, to regain compliance with the Equity Standard Rule.
Trading in the Company’s common stock will be
suspended on Nasdaq effective with the open of business on October
8, 2024. As a result, the Company expects its common stock to begin
trading on the Pink Open Market operated by the OTC Markets Group,
Inc. (commonly referred to as the “pink sheets”). There can be no
assurance that a broker will continue to make a market in the
Company’s common stock or that trading of the common stock will
continue on an over-the-counter market or elsewhere.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative medicines for
patients with CNS disorders. The Company has one approved product
in the United States, OLINVYK® (oliceridine) injection,
indicated in adults for the management of acute pain severe enough
to require an intravenous opioid analgesic and for whom alternative
treatments are inadequate. The Company’s novel pipeline is based on
Nobel Prize winning research and includes three differentiated
investigational drug candidates: TRV045 for diabetic neuropathic
pain and epilepsy, TRV250 for the acute treatment of migraine and
TRV734 for maintenance treatment of opioid use disorder.
For more information, please
visit www.Trevena.com
For more information, please contact:
Company Contact:Bob YoderSVP and Chief Business
OfficerTrevena, Inc.(610) 354-8840
Trevena (NASDAQ:TRVN)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Trevena (NASDAQ:TRVN)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024